Navigation Links
In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
Date:5/14/2013

BURLINGTON, Mass., May 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influences their prescribing decisions for relapsed/refractory multiple myeloma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought leaders are optimistic that the CRd regimen— carfilzomib (Onyx Pharmaceuticals/Ono Pharmaceutical's Kyprolis) in combination with lenalidomide (Celgene's Revlimid) and dexamethasone—will show advantages over sales-leading lenalidomide plus dexamethasone (the Rd regimen) on this attribute in the ongoing Phase III ASPIRE trial.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled As Carfilzomib and Pomalidomide Make Inroads Into the Market, What Key Attributes Will Differentiate Emerging Therapies According to Hematological Oncologists and Payers? finds that surveyed U.S. managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over Rd—a premium-priced standard-of-care regimen for relapsed/refractory multiple myeloma—to justify their cost and secure reimbursement. Notably, half of surveyed payers would not reimburse a new therapy priced the same as Rd or higher that offers a three-month improvement in overall survival over Rd, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European hematological oncologists identified neurotoxicity as the safety
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. Hobart Group Holdings Marks 10th Anniversary With Multiple Milestones
4. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
5. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
6. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
7. Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
8. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
9. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
10. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
11. MedNet Solutions To Participate In Multiple Clinical Research Conferences In April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... held biotech company that designs and develops novel ... management of cancer, announced today the completion of ... The financing included new investors RusnanoMedInvest (RMI) and ... Fund, and Pfizer Venture Investments, as well as ...
(Date:7/30/2014)... , July 30, 2014 ... and CUDA programming expertise to big data, aerospace ... eInfochips, a leading engineering R&D services ... to develop NVIDIA GPU-powered solutions for aerospace ... high-performance computing (HPC), industrial , and ...
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual Adventure ... 12-14, following two years in the high Colorado Plateau. ... and able-bodied athletes competing together in an inclusive outdoor ... experienced adventure athletes. , Hosted at the rustic ... River in the rugged Gore Mountains northwest of Vail, ...
(Date:7/31/2014)... July 31, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is looking at 10 tips ... , “Addiction recovery is a lifelong process, and one ... be committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... When guests shop CVS, they’ll find many ... Shea Moisture. And now CVS is adding another acclaimed brand ... 1, guests will find G Natural products in CVS stores ... CEO Roger Gore was inspired to start G’Natural Herbal Products ... developing a receding hairline; he tried many products on the ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 Push to ... ninth annual national “Shop For A Cause” charity shopping ... Cause” is a unique one-day-only shopping event created to ... more than $44 million for charities across the country ... by purchasing shopping passes from Push to Walk now. ...
(Date:7/30/2014)... July 31, 2014 Responding to ... environment more responsive to an increasingly diverse patient ... experience and scholarly expertise to the publication of ... care professions: "Diversity and Cultural Competence in Health ... L. Dreachslin, PhD, a professor in the Management ...
Breaking Medicine News(10 mins):Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... , , , LOUISVILLE, Ky., July ... regional provider of home health nursing services, announced today that it will ... on Wednesday, August 5, 2009, before the market open. , , ... 11:00 a.m. ET on August 5, 2009, and will be hosted by ...
... , WASHINGTON, July 31 Last ... Democratic leadership,s health care bill, H.R. 3200, that would specifically include ... of this bill. Family Research Council Action President Tony Perkins had ... Energy and Commerce Committee mark up: , , ...
... , , , , ... , HARRISBURG, Pa., July 31 Department of ... observance of National Immunization Awareness Month. , , ... sure you and your family are up-to-date on these immunizations is ...
... , , , ... statement by Jim O,Hara, Director, Produce Safety Project: , , ... the safety of fresh produce. The proposed guidance documents put out ... that the agency will finalize these documents quickly. We also look ...
... linked to headache, researchers explain , FRIDAY, July 31 ... cosmetic surgery, Michelle Cramer has now lost most of ... her frown lines. , Cramer, a graphics illustrator in ... close to a decade until she had surgery to ...
... , , , ABA program ... CALDWELL, N.J., July 31 Caldwell College will launch ... Analysis (ABA), a well developed scientific discipline that is best known ... disorder. Caldwell,s program was recently approved by the New Jersey ...
Cached Medicine News:Health News:Almost Family, Inc. to Report Second Quarter 2009 Financial Results on August 5, 2009 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Plastic Surgery Technique Might Ease Migraines 2Health News:Plastic Surgery Technique Might Ease Migraines 3Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2
... Merit Medical is pleased to offer ... The pre-coated, high-performance, InQwire guide wire ... is very lubricious and can help ... available in a wide range of ...
... The MULTI-LINK VISION Coronary Stent System ... of cobalt chromium stents. Cobalt chromium is ... so a cobalt chromium stent can have ... stainless steel stent with struts that are ...
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: